5th September 2023 6:00PM BST - Virtual
A BTK inhibitor with a difference – Shaping the future of CLL treatment
This meeting was a live-streaming event in which expert clinicians discussed BRUKINSA®▼, a
next-generation BTK inhibitor, as a treatment option for patients with CLL. The agenda and speaker information can be found below.
Topics included:
- Clinical evidence supporting the use of BRUKINSA
- Patient case studies
- The use of BRUKINSA in the NHS
Agenda
Recordings
BRUKINSA® : A next-generation BTK inhibitor – Dr Talha Munir
BSH Guidelines: BRUKINSA® in CLL – Dr Renata Walewska
When should BRUKINSA® be your BTK inhibitor of choice? – Panel discussion and Q&A
Speakers
Dr Piers Patten
Consultant Haematologist, King’s College Hospital, England
Dr Patten is a Clinician Scientist with a specialist interest in CLL and related lymphomas. He was appointed as a Consultant Haematologist at King’s College Hospital in 2013 and manages patients with lymphoma, particularly patients with CLL, at King’s Health Partners hospitals. He runs multiple clinical trials, working closely with the UK NIHR clinical trial groups, and has co-authored multiple national guidelines.
Dr Renata Walewska
Consultant Haematologist, UH Dorset NHS Foundation Trust, Chair, UK CLL, England
Dr Walewska has been a Consultant Haematologist at the Royal Bournemouth Hospital since 2010. Since March 2019 she has chaired the UK CLL Forum. In addition, she is part of the writing committee that updated the national BSH CLL guidelines and is an invited clinical advisor to the Evidence Review Group for NICE appraisals.
Dr Dima El-Sharkawi
Consultant Haematologist, The Royal Marsden NHS Foundation Trust, England
Dr El-Sharkawi was appointed as a Consultant Haematologist at the Royal Marsden Hospital in 2017. She has been an investigator on multiple clinical research studies and is Clinical Lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at The Royal Marsden. She is a member of the NCRI national lymphoma and CLL trials groups and has co-authored national guidelines for the diagnosis and management of T-cell lymphoma and Waldenström’s macroglobulinaemia.
Dr Talha Munir
Consultant Haematologist, Leeds Teaching Hospitals NHS Trust, England
Dr Munir has worked in the Leeds NHS trust since 2014 as Consultant Haematologist. His main clinical and research interests are in CLL and paroxysmal nocturnal haemoglobinuria (PNH). He is one of the PNH consultants working in the PNH National Service, a sub-investigator for the NCRI CLL clinical trials and he is involved in multiple studies at Leeds Teaching Hospital.